Elvire Pons‐Tostivint

2.3k total citations
47 papers, 764 citations indexed

About

Elvire Pons‐Tostivint is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Elvire Pons‐Tostivint has authored 47 papers receiving a total of 764 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 29 papers in Pulmonary and Respiratory Medicine and 10 papers in Molecular Biology. Recurrent topics in Elvire Pons‐Tostivint's work include Lung Cancer Treatments and Mutations (22 papers), Lung Cancer Research Studies (15 papers) and Cancer Immunotherapy and Biomarkers (13 papers). Elvire Pons‐Tostivint is often cited by papers focused on Lung Cancer Treatments and Mutations (22 papers), Lung Cancer Research Studies (15 papers) and Cancer Immunotherapy and Biomarkers (13 papers). Elvire Pons‐Tostivint collaborates with scholars based in France, United States and Spain. Elvire Pons‐Tostivint's co-authors include Julie Guillermet‐Guibert, Benoît Thibault, Anne Pradines, Julien Mazières, Nicolas Guibert, Olivier Calvayrac, Christophe Le Tourneau, Jaafar Bennouna, Marc G. Denis and Caroline Even and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Respiratory Journal.

In The Last Decade

Elvire Pons‐Tostivint

40 papers receiving 753 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elvire Pons‐Tostivint France 13 468 351 238 134 87 47 764
Amy Prawira Canada 11 326 0.7× 147 0.4× 172 0.7× 111 0.8× 62 0.7× 38 621
Minsig Choi United States 14 360 0.8× 134 0.4× 190 0.8× 104 0.8× 82 0.9× 28 549
Bin-Chi Liao Taiwan 15 553 1.2× 561 1.6× 217 0.9× 118 0.9× 37 0.4× 36 791
Wei‐Bang Guo China 11 445 1.0× 462 1.3× 124 0.5× 167 1.2× 35 0.4× 29 662
Bernhard Heinrich Germany 14 439 0.9× 187 0.5× 160 0.7× 66 0.5× 52 0.6× 36 630
Daniel Brattström Sweden 17 451 1.0× 401 1.1× 365 1.5× 237 1.8× 130 1.5× 43 874
Manyu Chen China 9 268 0.6× 98 0.3× 238 1.0× 170 1.3× 56 0.6× 15 581
Tejas Patil United States 16 544 1.2× 624 1.8× 228 1.0× 161 1.2× 66 0.8× 67 836
Julio A. Peguero United States 12 368 0.8× 241 0.7× 133 0.6× 78 0.6× 19 0.2× 49 517
Liru He China 18 159 0.3× 263 0.7× 410 1.7× 197 1.5× 162 1.9× 54 758

Countries citing papers authored by Elvire Pons‐Tostivint

Since Specialization
Citations

This map shows the geographic impact of Elvire Pons‐Tostivint's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elvire Pons‐Tostivint with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elvire Pons‐Tostivint more than expected).

Fields of papers citing papers by Elvire Pons‐Tostivint

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elvire Pons‐Tostivint. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elvire Pons‐Tostivint. The network helps show where Elvire Pons‐Tostivint may publish in the future.

Co-authorship network of co-authors of Elvire Pons‐Tostivint

This figure shows the co-authorship network connecting the top 25 collaborators of Elvire Pons‐Tostivint. A scholar is included among the top collaborators of Elvire Pons‐Tostivint based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elvire Pons‐Tostivint. Elvire Pons‐Tostivint is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pons‐Tostivint, Elvire, Thomas Goronflot, Perrine Créquit, et al.. (2024). Second-line treatment outcomes following first-line chemotherapy plus immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC): A multicenter study.. Journal of Clinical Oncology. 42(16_suppl). e20122–e20122. 1 indexed citations
2.
Jänne, Pasi A., Toshio Kubo, Kiichiro Ninomiya, et al.. (2024). Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02.. Journal of Clinical Oncology. 42(16_suppl). 8543–8543. 4 indexed citations
3.
4.
5.
Sands, Jacob, Aaron Lisberg, Aditya Bardia, et al.. (2024). Analysis of drug-related interstitial lung disease (ILD) inpatients (pts) treated with datopotamab deruxtecan (Dato-DXd).. Journal of Clinical Oncology. 42(16_suppl). 8623–8623. 4 indexed citations
6.
Herbst, Roy S., Byoung Chul Cho, Caicun Zhou, et al.. (2023). 64O Lenvatinib plus pembrolizumab, pemetrexed, and a platinum (len + pembro + chemo) as first-line therapy for metastatic non squamous non-small cell lung cancer (NSCLC): Phase III LEAP-006 study. Immuno-Oncology Technology. 20. 100536–100536. 3 indexed citations
7.
8.
Goronflot, Thomas, Sandrine Hiret, Ludovic Doucet, et al.. (2023). Prognostic Impact of TP53 Mutations in Metastatic Nonsquamous Non–small-cell Lung Cancer. Clinical Lung Cancer. 25(3). 244–253.e2. 7 indexed citations
9.
10.
Guillouzouic, A., et al.. (2022). A fatal case associated with Catabacter hongkongensis bacteremia in lung cancer patient: A case report. IDCases. 29. e01535–e01535. 4 indexed citations
11.
Pons‐Tostivint, Elvire, et al.. (2021). Homozygous Co-Deletion of Type I Interferons and CDKN2A Genes in Thoracic Cancers: Potential Consequences for Therapy. Frontiers in Oncology. 11. 695770–695770. 12 indexed citations
12.
Paolettí, Xavier, Vincent Servois, Patricia Tresca, et al.. (2021). Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy. Drugs in R&D. 21(4). 399–406. 15 indexed citations
13.
14.
Pons‐Tostivint, Elvire, et al.. (2020). Is there a role for locoregional treatment of the primary tumor in de novo metastatic breast cancer in the era of tailored therapies?. Critical Reviews in Oncology/Hematology. 157. 103146–103146. 9 indexed citations
15.
Carton, Matthieu, Luc Cabel, Anne Patsouris, et al.. (2020). 281MO Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database. Annals of Oncology. 31. S353–S353. 2 indexed citations
16.
Verhoest, G., Bastien Cabarrou, P. Coloby, et al.. (2020). Quality of life and functional outcomes after radical cystectomy with ileal orthotopic neobladder replacement for bladder cancer: a multicentre observational study. World Journal of Urology. 39(7). 2525–2530. 15 indexed citations
17.
Pons‐Tostivint, Elvire, Laëtitia Daubisse‐Marliac, Pascale Grosclaude, et al.. (2019). Multidisciplinary team meeting and EUSOMA quality indicators in breast cancer care: A French regional multicenter study. The Breast. 46. 170–177. 13 indexed citations
18.
Saleh, Khalil, Amaury Daste, Nicolas Martin, et al.. (2019). Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. European Journal of Cancer. 121. 123–129. 118 indexed citations
19.
Pons‐Tostivint, Elvire, Benoît Thibault, & Julie Guillermet‐Guibert. (2017). Targeting PI3K Signaling in Combination Cancer Therapy. Trends in cancer. 3(6). 454–469. 108 indexed citations
20.
Jacot, William, Elvire Pons‐Tostivint, Jean‐Sébastien Frenel, et al.. (2016). Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. Breast Cancer Research and Treatment. 157(2). 307–318. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Amy Prawira Breakdown of academic impact, for papers by Minsig Choi Breakdown of academic impact, for papers by Bin-Chi Liao Breakdown of academic impact, for papers by Wei‐Bang Guo Breakdown of academic impact, for papers by Bernhard Heinrich Breakdown of academic impact, for papers by Daniel Brattström Breakdown of academic impact, for papers by Manyu Chen Breakdown of academic impact, for papers by Tejas Patil Breakdown of academic impact, for papers by Julio A. Peguero Breakdown of academic impact, for papers by Liru He
Rankless by CCL
2026